A New Sugar-Based Freezing Technique Could Widen Access to CAR-T Cell Therapy

What This Article Covers

MIT researchers have published a sugar-based, DMSO-free cryopreservation method that lets CAR-T cells be thawed and infused without extra processing — an early-stage but promising technical fix for one of cell therapy's quieter bottlenecks. We look at what the study actually showed, why manufacturing and logistics (not just the cells' biology) determine how many patients can get CAR-T therapy at all, and what a separate September 2026 industry analysis reveals about the broader "scale-out" problem still standing between CAR-T and the patients who need it.

The Problem Hiding Behind the Headlines

CAR-T cell therapies for lymphoma, leukemia, and multiple myeloma have some of the most dramatic response rates in oncology, but the therapies remain geographically and logistically out of reach for a large share of patients. According to MIT News, only about 5% of U.S. hospitals currently have the capacity to manufacture and administer CAR-T cells on-site. For everyone else, a patient's own T cells must be collected, frozen, shipped to a manufacturing site (often hundreds or thousands of miles away), engineered, frozen again, shipped back, and thawed — all while the patient's cancer continues to progress. A companion September 1, 2026 analysis in PharmaVoice frames this plainly: CAR-T's core scaling challenge "isn't producing larger batches — it's managing thousands of individualized patient-specific manufacturing runs as a cohesive system," or as one industry expert put it, "you don't scale up, you scale out."

The New Technique: Freezing With Sugar Instead of Solvent

The conventional way to cryopreserve CAR-T cells uses dimethyl sulfoxide (DMSO), a chemical solvent that protects cells from ice-crystal damage during freezing but must be washed out of the product before it can be infused — a processing step many smaller or community hospitals are not equipped to perform. Researchers at MIT's Koch Institute for Integrative Cancer Research, led by Ana Jaklenec and Robert Langer, with postdoctoral researchers Amy Lee and Khanh Tran as co-lead authors, describe a different approach in the August 19, 2026 issue of Trends in Biotechnology: using naturally occurring sugars — trehalose and sucrose — as the primary cryoprotectant instead. Because sugar molecules don't normally cross a cell's membrane, the team used electroporation (a brief electrical pulse that opens temporary pores in the cell membrane) to load the sugars inside, mimicking a strategy some Arctic organisms use to survive freezing temperatures in the wild.

"With this approach, you could theoretically just thaw the cells and then inject them, without any extra processing steps," Jaklenec said, as reported by MIT News. Lee added: "You don't need to remove the cryoprotectants. You could use the cells upon thawing." In the reported experiments, sugar-preserved CAR-T cells showed higher post-thaw viability than DMSO-preserved cells, and in mouse models of lymphoma and glioblastoma, mice treated with the sugar-preserved cells had improved survival compared to controls.

What This Would Mean if It Holds Up

If a cryoprotectant that doesn't need to be washed out proves safe and effective in humans, it could remove one of the practical barriers keeping CAR-T manufacturing and administration concentrated at a small number of specialized academic centers — potentially letting more community hospitals handle the final thaw-and-infuse step themselves rather than referring patients hundreds of miles away. Co-lead author Khanh Tran framed the finding as part of a broader manufacturing lesson: "We believe that our findings underscore the importance of thorough characterization and optimization of every stage of cell therapy manufacturing," according to Scientific Frontline's coverage of the study.

The Caveat That Matters Most

This is early-stage, preclinical work, and it should be read that way. As Al Día News noted in its coverage of the MIT findings, "there is not yet evidence from human patients showing that [the technique] improves cancer treatment outcomes" — the results so far come from cell-viability assays and mouse models, not clinical trials. Moving a new cryopreservation method into actual CAR-T manufacturing means clearing additional regulatory, quality-control, and clinical-validation hurdles before any hospital could use it on patients. And even if the technique succeeds, it addresses only one link in a much longer chain — cell collection, engineering, quality release testing, shipping logistics, and treatment-center staffing all remain separate constraints on how many patients can be treated and how quickly.

The Bigger Manufacturing Picture, as of September 2026

The PharmaVoice analysis, published September 1, 2026, offers a useful reality check on how far the field has already come on the logistics side — and how far it still has to go. It reports that one leading BCMA-directed CAR-T therapy is now manufactured with a 99% success rate and a median U.S. turnaround time of 29 days, available through 348 treatment sites across 19 markets, with expanded facilities capable of manufacturing for up to 10,000 patients annually. Regulatory changes have helped, too: the FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) requirements for all approved CD19- and BCMA-directed CAR-T therapies in June 2025 and shortened the required post-treatment monitoring window from four weeks to two, changes that a related September 2026 AJMC analysis says are "facilitating decentralized delivery in community settings" and reducing the burden on patients who previously had to stay near a treatment center for a month after infusion.

At the same time, cost remains a genuine and unresolved barrier. The AJMC analysis notes that CAR-T treatment expenses "can exceed $1 million" per patient when factoring in the therapy itself, hospitalization, and management of side effects, and that reimbursement complexity and payer-policy variability continue to slow treatment initiation even at sites that are otherwise equipped to deliver it. In vivo CAR-T approaches — which would reprogram T cells inside a patient's body rather than manufacturing them externally — are cited by multiple sources as a longer-term possibility for sidestepping much of today's manufacturing burden, but these remain in early clinical development and are not close to standard use.

Bottom Line

Real, incremental progress is being made on the unglamorous but consequential problem of getting CAR-T cell therapy to more patients — through smarter cryopreservation science, faster and more distributed manufacturing, and regulatory changes that reduce the burden of receiving treatment. The MIT sugar-cryopreservation technique is a genuinely promising piece of that puzzle, but it is still a laboratory and mouse-model finding, not a validated clinical tool, and it does nothing on its own to address the roughly seven-figure cost of CAR-T therapy or the payer-policy hurdles that remain separate obstacles to access. Patients and clinicians should watch this space with real but measured optimism: manufacturing logistics are improving on several fronts at once, but "more accessible" CAR-T therapy is still being built one incremental, unglamorous step at a time.